Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from In vitro and In vivo Oncology

  • You have access
    CUB domain containing protein 1 is a target for radioligand therapy in multiple bladder cancer subtypes, including Nectin-4 and TROP2 null disease
    Shalini Chopra, James Wells, Jie Zhou, Jonathon Chou and Michael Evans
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2563;
  • You have access
    Research of an extracellular matrix-targeting antibody carrier for molecular imaging of pancreatic ductal adenocarcinoma
    Zhixin Hao, Wenjia Zhu, Na Niu, Mei Zhang, Lei You, Jie Ding, Taiping Zhang, Yupei Zhao and Li Huo
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2571;
  • You have access
    Antibody radioconjugates in combination with CD47 Immunotherapy Improves Antitumor Efficacy in preclinical models of solid tumors
    Jason Li, Megan McCloskey, Caroline Jennings, Sagarika Pachhal, Emily Greer, Amanda Chin, Eileen Geoghegan, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen, Dale Ludwig, Helen Kotanides and Denis Beckford
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2574;
  • You have access
    A CXCR4-Targeting Radiotheranostic Based on a Potent Novel Peptide Antagonist
    Daniel Kwon, Ingrid Bloise, Zhengxing Zhang, Ruiyan Tan, Ryan Wilson, Nadine Colpo, Helen Merkens, Jutta Zeisler, Kuo-Shyan Lin and Francois Benard
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2566;
  • You have access
    Theranostic role of 89Zr/177Lu-labeled aflibercept in breast cancer
    Lei Kang, Qi Yang, Zhao Chen, Yongkang Qiu, Wenpeng Huang, Lele Song and YAN FAN
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2562;
  • You have access
    FAP-targeted molecular radiotherapy synergizes with checkpoint inhibitor immunotherapy to attenuate tumor growth in a murine model of non-small cell lung cancer
    Kathleen Capaccione, Mikhail Doubrovin, Brian Braumuller, Dev Leibowitz, Nikunj Bhatt, Andrei Molotkov, Fatemeh Momen-Heravi and Akiva Mintz
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2564;
  • You have access
    Longitudinal multi-tracer PET/CT characterization of oncogene-driven hepatocellular carcinoma formation in two transgenic mouse models
    Mari Teuter, Asha Balakrishnan, Daniel Ahrens, Tobias Ross, Michael Ott, Frank Bengel and Jens Bankstahl
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2577;

Pages

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
SNMMI

© 2025 SNMMI

Powered by HighWire